Evaluation of Extensive Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Epithelial Ovarian Cancer

Abstract

Hyperthermic intraperitoneal chemotherapy after extensive CRS for advanced EOC is feasible with acceptable morbidity and mortality. Complete cytoreduction may improve survival in highly selected patients. Additional follow-up and further studies are needed to determine the effects of HIPEC on survival.

Technique of Post- Operative HIPEC (Hyperthermic Intraperitoneal Chemotherapy) using Veress Needle and IVFluid Warmer In Patients With Epithelial Ovarian Cancer

“…Abdominal pain (18.91%) in our study could be partly because of higher dose of paclitaxel used, as reported in other studies [4]. Although we used higher doses of chemotherapeutic drugs severe complications like renal failure were not observed, which were observed in other studies [3]. This could be because of using drugs IP/iv at alternative cycles and adding carboplatin instead of cisplatin for iv use.…”

“…We report results of 74 hyperthermic IP instillations postoperatively in 14 patients with EOC using Veress needle and IVFluid warmer. This is a simple procedure compared to complex procedure of intraoperative HIPEC used in many centers [3]. 11 out of 14 patients completed all 6 cycles of planned postoperative HIPEC.…”

Hyperthermic intraperitoneal chemotherapy (HIPEC) and neoadjuvant chemotherapy as prophylaxis of peritoneal carcinosis from advanced gastric cancer—effects on overall and disease free survival

“…It has been investigated by previous studies (38). The association of cisplatin and paclitaxel in hyperthermic IPC has been previously described in ovarian cancer (16,17). It demonstrated to not increase the morbidity and the two molecules do not impair each other penetration and effects (18).…”

“…No previous reports about the combined use of cisplatin and paclitaxel in hyperthermic regimen exist in AGC. The combination of cisplatin and paclitaxel has been previously described in the management of ovarian cancer (16,17) with good data about its penetration in hyperthermic administration (18).…”

The Role of Systemic Chemotherapy

“…Ansaloni et al collected data from a prospective phase II trial assessing 39 patients with primary or recurrent peritoneal OC carcinomatosis receiving cytoreductive surgery plus HIPEC. Median DFS was 14 months; microscopically complete cytoreduction was achieved for 35 patients (90 %) [36].…”